Literature DB >> 32945258

The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies.

Jennifer El Diaz1,2,3, Mehmet Eren Ahsen1,3,4, Thomas Schaffter1,3, Xintong Chen1, Ronald B Realubit5,6, Charles Karan5,6, Andrea Califano5,7,8,9, Bojan Losic1,10,11,12, Gustavo Stolovitzky1,3,5,7.   

Abstract

Our ability to discover effective drug combinations is limited, in part by insufficient understanding of how the transcriptional response of two monotherapies results in that of their combination. We analyzed matched time course RNAseq profiling of cells treated with single drugs and their combinations and found that the transcriptional signature of the synergistic combination was unique relative to that of either constituent monotherapy. The sequential activation of transcription factors in time in the gene regulatory network was implicated. The nature of this transcriptional cascade suggests that drug synergy may ensue when the transcriptional responses elicited by two unrelated individual drugs are correlated. We used these results as the basis of a simple prediction algorithm attaining an AUROC of 0.77 in the prediction of synergistic drug combinations in an independent dataset.
© 2020, Diaz et al.

Entities:  

Keywords:  LNCaP; MCF7; cancer biology; cell biology; computational biology; drug synergy; human; rna-seq; systems biology; transcriptomics

Mesh:

Substances:

Year:  2020        PMID: 32945258      PMCID: PMC7546737          DOI: 10.7554/eLife.52707

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  93 in total

1.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features.

Authors:  Yang Liao; Gordon K Smyth; Wei Shi
Journal:  Bioinformatics       Date:  2013-11-13       Impact factor: 6.937

2.  Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

Authors:  Antonio C Wolff; Ann A Lazar; Igor Bondarenko; August M Garin; Stephen Brincat; Louis Chow; Yan Sun; Zora Neskovic-Konstantinovic; Rodrigo C Guimaraes; Pierre Fumoleau; Arlene Chan; Soulef Hachemi; Andrew Strahs; Maria Cincotta; Anna Berkenblit; Mizue Krygowski; Lih Lisa Kang; Laurence Moore; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 44.544

3.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

4.  Suppression of autophagy exacerbates Mefloquine-mediated cell death.

Authors:  Ji Hyun Shin; So Jung Park; Yoon Kyung Jo; Eun Sung Kim; Hee Kang; Ji-Ho Park; Eunjoo H Lee; Dong-Hyung Cho
Journal:  Neurosci Lett       Date:  2012-03-21       Impact factor: 3.046

5.  Inconsistency in large pharmacogenomic studies.

Authors:  Benjamin Haibe-Kains; Nehme El-Hachem; Nicolai Juul Birkbak; Andrew C Jin; Andrew H Beck; Hugo J W L Aerts; John Quackenbush
Journal:  Nature       Date:  2013-11-27       Impact factor: 49.962

6.  Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.

Authors:  Zhichao Tang; Shaoxiong Niu; Fei Liu; Kejing Lao; Jingshan Miao; Jinzi Ji; Xiang Wang; Ming Yan; Luyong Zhang; Qidong You; Hong Xiao; Hua Xiang
Journal:  Bioorg Med Chem Lett       Date:  2014-03-22       Impact factor: 2.823

Review 7.  TGFbeta regulated gene expression by Smads and Sp1/KLF-like transcription factors in cancer.

Authors:  Volker Ellenrieder
Journal:  Anticancer Res       Date:  2008 May-Jun       Impact factor: 2.480

8.  Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent.

Authors:  Natasha Sharma; Simmy Thomas; Encouse B Golden; Florence M Hofman; Thomas C Chen; Nicos A Petasis; Axel H Schönthal; Stan G Louie
Journal:  Cancer Lett       Date:  2012-08-01       Impact factor: 8.679

9.  Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.

Authors:  Xinyu Li; Chengzhe Wu; Xin Lin; Xuerong Cai; Linyi Liu; Guoshun Luo; Qidong You; Hua Xiang
Journal:  Eur J Med Chem       Date:  2018-10-19       Impact factor: 6.514

10.  Repurposing Cationic Amphiphilic Antihistamines for Cancer Treatment.

Authors:  Anne-Marie Ellegaard; Christian Dehlendorff; Anna C Vind; Atul Anand; Luise Cederkvist; Nikolaj H T Petersen; Jesper Nylandsted; Jan Stenvang; Anders Mellemgaard; Kell Østerlind; Søren Friis; Marja Jäättelä
Journal:  EBioMedicine       Date:  2016-06-07       Impact factor: 11.205

View more
  8 in total

1.  The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies.

Authors:  Jennifer El Diaz; Mehmet Eren Ahsen; Thomas Schaffter; Xintong Chen; Ronald B Realubit; Charles Karan; Andrea Califano; Bojan Losic; Gustavo Stolovitzky
Journal:  Elife       Date:  2020-09-18       Impact factor: 8.140

2.  Metabolomics-based phenotypic screens for evaluation of drug synergy via direct-infusion mass spectrometry.

Authors:  Xiyuan Lu; G Lavender Hackman; Achinto Saha; Atul Singh Rathore; Meghan Collins; Chelsea Friedman; S Stephen Yi; Fumio Matsuda; John DiGiovanni; Alessia Lodi; Stefano Tiziani
Journal:  iScience       Date:  2022-04-07

Review 3.  Independent Drug Action in Combination Therapy: Implications for Precision Oncology.

Authors:  Deborah Plana; Adam C Palmer; Peter K Sorger
Journal:  Cancer Discov       Date:  2022-03-01       Impact factor: 38.272

4.  PARP1-Inhibition Sensitizes Cervical Cancer Cell Lines for Chemoradiation and Thermoradiation.

Authors:  Marloes IJff; Gregor G W van Bochove; Denise Whitton; Roy Winiarczyk; Celina Honhoff; Hans Rodermond; Johannes Crezee; Lukas J A Stalpers; Nicolaas A P Franken; Arlene L Oei
Journal:  Cancers (Basel)       Date:  2021-04-26       Impact factor: 6.639

5.  Transcriptome-Wide Prediction and Measurement of Combined Effects Induced by Chemical Mixture Exposure in Zebrafish Embryos.

Authors:  A Schüttler; G Jakobs; J M Fix; M Krauss; J Krüger; D Leuthold; R Altenburger; W Busch
Journal:  Environ Health Perspect       Date:  2021-04-07       Impact factor: 9.031

6.  Interaction between Rag genes results in a unique synergistic transcriptional response that enhances soybean resistance to soybean aphids.

Authors:  Martha I Natukunda; Jessica D Hohenstein; Chantal E McCabe; Michelle A Graham; Yunhui Qi; Asheesh K Singh; Gustavo C MacIntosh
Journal:  BMC Genomics       Date:  2021-12-11       Impact factor: 3.969

7.  A novel network based linear model for prioritization of synergistic drug combinations.

Authors:  Jiaqi Li; Hongyan Xu; Richard A McIndoe
Journal:  PLoS One       Date:  2022-04-05       Impact factor: 3.240

8.  Deep neural network prediction of genome-wide transcriptome signatures - beyond the Black-box.

Authors:  Rasmus Magnusson; Jesper N Tegnér; Mika Gustafsson
Journal:  NPJ Syst Biol Appl       Date:  2022-02-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.